Investor Presentation

27.07.2026 National Stock Exchange of India Limited BSE Limited “Exchange Plaza”, Floor- 25, P J Tower, Bandra-Kurla Complex, Dalal Street, Bandra (East) Mumbai 400 051 Mumbai 400 001 SYMBOL:- EPIGRAL Scrip Code: 543332 Dear Sirs, Sub.: Investors Presentation on Un-Audited Financial Results – Q1 FY27 Ref.: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Investors Presentation on Un-Audited Financial Results – Q1 FY27. The said Earnings Presentation is also available at www.epigral.com in the Investor Relations section. This is for information and records. Thanking you, Yours faithfully, For Epigral Limited Gaurang Trivedi Company Secretary & Compliance Officer M. No. 22307 Epigral Limited Investor Presentation – Q1FY2027 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Epigral Limited (the “Company”) solely for the information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company Certain statements in this presentation concerning our future growth prospects are forward looking statements which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The Risk and uncertainties relating to the statements include, but are not limited to, risks and uncertainties regarding fiscal policy, competition, inflationary pressures and general economic conditions affecting demand / supply and price conditions in domestic and international markets. The company does not undertake to update any forward -looking statement that may be made from time to time by or on behalf of the company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. The Company does not make any promise to update/provide such presentation along with results to be declared in the coming years. Q1FY27 Result update Key Highlights Q1FY27 Key Highlights: o YoY sales volume grew by 5% and overall plant utilization stood above 80% o Revenue stood at ₹ 709 Crore, a 15% growth, due to volume growth and improved realization o Absolute EBITDA grew by 10% to ₹ 179 Crore vs ₹ 163 Crore in Q1FY26. EBITDA margin stood at 25% o PAT rose by 25% to ₹ 99 Crore vs ₹ 79 Crore in Q1FY26. PAT margin stood at 14% o ROCE stood at 16% in Q1FY27 compared to 24% in Q1FY26 due to lower EBIT in TTM and a sizeable CWIP o Net Debt/EBITDA stood at 0.8x as on 30th June 2026 Q1FY27 Strategic Highlights: o Epigral’s board approved capex in below two projects, which are expected to commission by H2FY28 • Epoxy Resin & Formulations plant with capacity of 1,25,000 TPA • Multi-Purpose Plant (MPP) downstream for Epichlorohydrin (ECH) and Chlorotoluene Value Chain o Epigral is also setting up pilot plant for Epoxy Resin & Formulations and MPP to optimise manufacturing process, validate product quality and facilitate customer approvals ahead of commercial scale production o Capex of enhancing CPVC Resin, ECH and Wind Solar Hybrid Power Plant capacity are moving as per schedule and are expected to get commissioned within the timeline and budget CMD Message “Epigral delivered steady growth in Q1FY27 despite severe macroeconomic volatility driven by geopolitical tensions in West Asia. The quarter was marked by fluctuations in raw material and finished goods prices, alongside elevated freight costs and shipment delays. Leveraging its diversified product mix, Epigral successfully navigated these headwinds to achieve 15% revenue growth and an EBITDA margin of 25%. While geopolitical challenges persist, operating conditions have stabilized. Backed by India’s strong economic growth trajectory, management maintains a positive outlook. To drive future diversified growth, the Board approved strategic investments in a new Epoxy Resin & Formulations plant and a Multi-Purpose Plant (MPP). Both expansions will enhance efficiency within Epigral’s integrated manufacturing complex by utilizing internal raw materials. Specifically, the Epoxy Resin plant will consume ECH and Caustic Soda, while the MPP will be downstream of ECH and Chlorotoluenes Value Chain. The Epoxy Resin plant will cater to domestic and global demand across the renewable energy, infrastructure, electronics, automotive, and industrial sectors. Concurrently, the MPP will meet rising domestic demand for pharmaceutical and agrochemical intermediates and water treatment chemicals. These investments reflect Epigral's ongoing commitment to building an integrated manufacturing platform and diversifying its portfolio to deliver long-term stakeholder value” - Mr. Maulik Patel, Chairman and Managing Director Q1FY27 Financial Highlights EBITDA PAT Revenue 13% 14% 82 79 Q4FY26 Q1FY26 Q1FY27 Q4FY26 Q1FY26 Q1FY27 Q4FY26 Q1FY26* Q1FY27 ₹ Crore Margin -% *As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 160 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 79 Cr Key ratios as on 30th June 2026 ROCE (%)*# ROE (%)* Net Debt/EBITDA (x)* 16% 16% 12% 12% Q4FY26 Q1FY26 Q1FY27 Q4FY26^ Q1FY26^ Q1FY27 Q4FY26 Q1FY26 Q1FY27 *TTM EBIT, PAT and EBITDA are considered for above ratios #Capital employed in ROCE includes Capital Work in Progress ^PAT considered here for ROE for Q1FY26 is of Rs. 79 Cr (instead of Rs. 160 Cr), after reducing it by Rs. 81 Cr for benefit of reduction in Deferred tax liability, as the company shifted to new tax rate of 25.17% from FY2026 Capex Plan Capex Plan: Epoxy Resin and Multi Purpose Plant Epoxy Resin & Formulations Multi Purpose Plant (MPP) Project Details Project Details o Capacity: 1,25,000 TPA o Downstream of Epichlorohydrin and Chlorotoluenes Value Chain o Location: Existing Complex, Dahej o Location: Exiting Complex, Dahej o Expected commissioning: H2FY28 o Expected commissioning: H2FY28 Rationale Rationale o Growing demand in India, expected to grow at double digit percentage o Import substitute products o Strengthening integrated complex: Epichlorohydrin o Strengthening integrated complex: ECH and and Caustic Soda are among the key raw materials Chlorotoluenes Value Chain will be consumed as o Catering to industries such as construction, renewables energy, automotive, electronics, o Catering to Agrochemical and Pharmaceuticals infrastructure, marine, aerospace, industrial flooring, Intermediates and Water Treatment Chemicals o Strengthening Epigral’s position in Specialty Chemicals Capex Plan: Enhancing CPVC and Epichlorohydrin CPVC Epichlorohydrin (ECH) Project Details Project Details o Additional capacity – 75,000 TPA o Additional capacity – 50,000 TPA o Total capacity after expansion – 1,50,000 TPA o Total capacity after expansion – 1,00,000 TPA (World’s largest plant by capacity) (India’s largest plant by capacity) o Expected commissioning – Q2FY27 o Expected commissioning – Q2FY27 Rationale Rationale o Demand in India is expected to grow at ~ 12% - 13% o Demand in India is expected to grow at high double CAGR digit % o Increasing Chlorine consumption in house, further o Increasing captive consumption of Chlorine, strengthening integrated complex Hydrogen and Caustic Soda, further strengthening integrated complex o For CPVC, Epigral has establish [Showing first 8,000 characters — download PDF for full document]